Phase 2/3 Trial of ATH-1017 for Mild or Moderate Alzheimer’s Enrolling

Phase 2/3 Trial of ATH-1017 for Mild or Moderate Alzheimer’s Enrolling

313806

Phase 2/3 Trial of ATH-1017 for Mild or Moderate Alzheimer’s Enrolling

Athira Pharma announced its Phase 2 ACT-AD trial is fully enrolled and its Phase 2/3 LIFT-AD trial has reached more than half of its target number. Both studies are evaluating the safety and efficacy of ATH-1017 in people with mild to moderate Alzheimer’s disease. Eligible adults, ages 55 to 85, are still being recruited for the LIFT-AD trial (NCT04488419) taking place across the U.S. It aims to enroll 300 patients; contact and site information is available here.…

You must be logged in to read/download the full post.